Organ function support in patients with coronavirus disease 2019: Tongji experience

Abstract

Coronavirus disease 2019 (COVID-19) is a highly contagious disease and a serious threat to human health. COVID-19 can cause multiple organ dysfunction, such as respiratory and circulatory failure, liver and kidney injury, disseminated intravascular coagulation, and thromboembolism, and even death. The World Health Organization reports that the mortality rate of severe-type COVID-19 is over 50%. Currently, the number of severe cases worldwide has increased rapidly, but the experience in the treatment of infected patients is still limited. Given the lack of specific antiviral drugs, multi-organ function support treatment is important for patients with COVID-19. To improve the cure rate and reduce the mortality of patients with severe- and critical-type COVID-19, this paper summarizes the experience of organ function support in patients with severe- and critical-type COVID-19 in Optical Valley Branch of Tongji Hospital, Wuhan, China. This paper systematically summarizes the procedures of functional support therapies for multiple organs and systems, including respiratory, circulatory, renal, hepatic, and hematological systems, among patients with severe- and critical-type COVID-19. This paper provides a clinical reference and a new strategy for the optimal treatment of COVID-19 worldwide.

Keywords

COVID-19 / severe and critical type / organ function support

References

[1] Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020 Mar 13. [Epub ahead of print] doi:10.1001/jamainternmed.2020.0994

[2] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-Infected pneumonia in wuhan, china. JAMA 2020; 323(11): 1061–1069

[3] National Health Commission of China. Diagnosis and treatment protocol for novel coronavirus pneumonia (7th interim edition). 2020. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7df-e4cef80dc7f5912eb1989/files/ce3e6945832a438eaae415350-a8ce964.pdf (in Chinese) (accessed March 4, 2020)

[4] Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, Deng Y, Wei S. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Chin J Tuberc Respir Dis (Zhonghua Jie He He Hu Xi Za Zhi) 2020 Feb 6. [Epub ahead of print] doi:10.3760/cma.j.issn.1001-0939.2020.0005 (in Chinese)

[5] Liu J, Liu Y, Xiang P, Pu L, Xiong HF, Li CS, Zhang M, Tan JB, Xu YL, Song R, Song MH, Wang L, Zhang W, Bing H, Yang L, Wang XJ, Zhou GQ, Zhang T, Li B, Wang YB, Chen ZH, Wang XB. Neutrophil-to-lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage. Medrxiv 2020; doi:10.1101/2020.02.10.20021584

[6] Sun TW, Shang Y. Chinese experts consensus on diagnosis and treatment of severe and critical new coronavirus pneumonia. Chin Crit Care Med (Zhonghua Wei Zhong Bing Ji Jiu Yi Xue) 2020; 32 [Epub ahead of print] (in Chinese)

[7] Guan XD, Qiu HB, Du B. Expert recommendations on severe type coronavirus disease 2019. Chin J Crit Care Intensive Care Med (Zhonghua Zhong Zheng Yi Xue Dian Zi Za Zhi) 2020; 6: (2020-3-1) (in Chinese)

[8] Zhao JP, Hu Y, Du RH, Cheng ZS, Jin Y, Zhou M, Zhang J, Qu JM, Cao B. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia. Chin J Tuberc Respir Dis (Zhonghua Jie He He Hu Xi Za Zhi) 2020 Feb 8. [Epub ahead of print] doi:10.3760/cma.j.issn.1001-0939.2020.0007 (in Chinese)

[9] Critical care committee of Chinese Association of Chest Physician; Respiratory and critical care group of Chinese Thoracic Society; Respiratory care group of Chinese Thoracic Society. Conventional respiratory support therapy for severe acute respiratory infections (SARI): clinical indications and nosocomial infection prevention and control. Chin J Tuberc Respir Dis (Zhonghua Jie He He Hu Xi Za Zhi) 2020 Feb 16. [Epub ahead of print] doi:10.3760/cma.j.issn.1001-0939.2020.0015 (in Chinese)

[10] Wang D, Jiang JG, Li S, Yan JT, Zhao CX, Wang Y, Ma YX, Zeng HS, Guo XM, Wang H, Tang JR, Zuo HJ, Lin L, Cui GL; Editorial Board of Chinese Journal of Cardiology; Working Group of Adult Fulminant Myocarditis. Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis. Sci China Life Sci 2019; 62(2): 187–202

[11] Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak — an update on the status. Mil Med Res 2020; 7(1): 11

[12] Joannidis M, Forni LG. Clinical review: timing of renal replacement therapy. Crit Care 2011; 15(3): 223

[13] Miao H, Shi J, Wang C, Lu G, Zhu X, Wang Y, Cui Y, Zhang Y. Continuous renal replacement therapy in pediatric severe sepsis: a propensity score-matched prospective multicenter cohort study in the PICU. Crit Care Med 2019; 47(10): e806–e813

[14] Putzu A, Fang MX, Boscolo Berto M, Belletti A, Cabrini L, Cassina T, Landoni G. Blood purification with continuous veno-venous hemofiltration in patients with sepsis or ARDS: a systematic review and meta-analysis. Minerva Anestesiol 2017; 83(8): 867–877

[15] Han F, Sun R, Ni Y, Hu X, Chen X, Jiang L, Wu A, Ma L, Chen M, Xv Y, Tu Y. Early initiation of continuous renal replacement therapy improves clinical outcomes in patients with acute respiratory distress syndrome. Am J Med Sci 2015; 349(3): 199– 205

[16] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507–513

[17] Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, Diaz G, Cohn A, Fox L, Patel A, Gerber SI, Kim L, Tong S, Lu X, Lindstrom S, Pallansch MA, Weldon WC, Biggs HM, Uyeki TM, Pillai SK; Washington State 2019-nCoV Case Investigation Team. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382(10): 929–936

[18] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497–506

Compliance with ethics guidelines

The authors declare that they have no conflicts of interest. This manuscript does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee.

Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.

RIGHTS & PERMISSIONS

2020 The Author(s) 2020. This article is published with open access at link.springer.com and journal.hep.com.cn